These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28092822)

  • 1. Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2
    Yang J; Samsel PA; Narov K; Jones A; Gallacher D; Gallacher J; Sampson JR; Shen MH
    Neoplasia; 2017 Feb; 19(2):112-120. PubMed ID: 28092822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
    Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
    BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
    Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
    Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
    Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
    BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2
    Jones AT; Narov K; Yang J; Sampson JR; Shen MH
    Neoplasia; 2019 Feb; 21(2):230-238. PubMed ID: 30622053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
    Budde K; Gaedeke J
    Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
    Yamamoto Y; De Velasco MA; Kura Y; Nozawa M; Hatanaka Y; Oki T; Ozeki T; Shimizu N; Minami T; Yoshimura K; Yoshikawa K; Nishio K; Uemura H
    J Transl Med; 2015 May; 13():150. PubMed ID: 25953027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
    Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1231-40. PubMed ID: 23455452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy.
    Ni J; Yan F; Qin W; Yu L; Zhang G; Liu F; Yang X; Yang B; Hao C; Wang T; Liu P; Yuan J; Wu G
    Sci Rep; 2019 Oct; 9(1):14337. PubMed ID: 31586081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
    Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus.
    Hasskarl J
    Recent Results Cancer Res; 2018; 211():101-123. PubMed ID: 30069763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
    Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
    Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H; Zhang C; Chi H; Meng Z
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.
    Kwiatkowski DJ; Palmer MR; Jozwiak S; Bissler J; Franz D; Segal S; Chen D; Sampson JR
    Eur J Hum Genet; 2015 Dec; 23(12):1665-72. PubMed ID: 25782670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2
    Jones AT; Yang J; Narov K; Henske EP; Sampson JR; Shen MH
    Neoplasia; 2019 Aug; 21(8):731-739. PubMed ID: 31207499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
    Woodrum C; Nobil A; Dabora SL
    J Transl Med; 2010 Feb; 8():14. PubMed ID: 20146790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
    Nakai Y; Miyake M; Morizawa Y; Hori S; Tatsumi Y; Anai S; Onishi S; Tanaka N; Fujimoto K
    Oncol Rep; 2017 Jan; 37(1):227-234. PubMed ID: 27840968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal phenotypes correlate with genotypes in unrelated individuals with tuberous sclerosis complex in China.
    Luo C; Zhang Y; Zhang YS; Zhang MX; Ning J; Chen MF; Li Y; Qi L; Zu XB; Li YL; Cai Y
    Orphanet J Rare Dis; 2022 Jul; 17(1):288. PubMed ID: 35870981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.